Placenta praevia Treatment

Understanding How Treatment Goals Shape Your Care

When placenta praevia is diagnosed, the treatment approach focuses on several important aims. The primary objective is to prevent or manage bleeding episodes that can occur when the placenta separates from the uterine wall. Healthcare providers work to extend the pregnancy as close to full term as possible, typically aiming for at least 36 weeks of gestation, which gives the baby time to develop fully while minimizing risks.1

Treatment strategies depend heavily on how far along the pregnancy is, how severe the bleeding episodes are, and whether the placenta is partially or completely covering the cervical opening. In many cases, especially when diagnosed early in pregnancy, the condition may resolve on its own as the uterus grows and the placenta moves upward away from the cervix. However, when placenta praevia persists into the later stages of pregnancy, planning for a safe delivery becomes the central focus.2

Medical societies and healthcare organizations have established guidelines for managing placenta praevia based on decades of clinical experience. These recommendations emphasize close monitoring, activity modification, and timely delivery when necessary. The treatment plan is always individualized, taking into account the mother's overall health, previous pregnancy history, and any complications that may arise.3

Standard Approaches to Managing Placenta Praevia

The standard treatment for placenta praevia does not involve medications that can change the position of the placenta, as there are no such treatments available. Instead, management focuses on reducing risks and preparing for the safest possible delivery. The specific approach varies depending on whether bleeding has occurred and how far along the pregnancy has progressed.4

For women diagnosed with placenta praevia who have not experienced bleeding, healthcare providers typically recommend significant lifestyle modifications. These may include reducing physical activities, avoiding strenuous exercise, and in some cases, complete bed rest. The goal is to minimize any actions that could trigger separation of the placenta from the uterine wall, which would cause bleeding. Women are advised to avoid sexual intercourse after 28 weeks of pregnancy, as this can trigger bleeding. Similarly, nothing should be inserted into the vagina—no tampons, douches, or internal examinations—to reduce the risk of disturbing the placenta.3

When bleeding does occur, the treatment becomes more intensive. Many women will be admitted to the hospital for close monitoring of both mother and baby. Healthcare teams track the baby's heart rate continuously and watch for signs of fetal distress, which means the baby is not getting enough oxygen. During hospitalization, women typically remain on bed rest, and their blood counts are checked regularly to ensure they are not losing too much blood.1

If bleeding is severe or continuous, a blood transfusion may be necessary to replace lost blood and maintain the mother's health. This is a standard medical procedure where donor blood is given through an intravenous line. Blood transfusions help prevent shock and ensure that both mother and baby receive adequate oxygen.3

In cases where the pregnancy has not yet reached 36 weeks and early delivery seems likely, doctors may administer corticosteroid injections. These medications, typically given as two shots over 24 to 48 hours, help speed up the development of the baby's lungs. This preparation is crucial because premature babies often struggle with breathing due to underdeveloped lungs. The corticosteroids can significantly improve the baby's chances of breathing independently after birth.4

Women with certain blood types may also receive an injection of a medicine called Rhogam. This is particularly important for women with Rh-negative blood type, as it prevents complications in future pregnancies. Rhogam prevents the mother's immune system from creating antibodies that could attack a baby's blood cells in subsequent pregnancies.3

Healthcare providers may also prescribe medications to prevent early labor if contractions begin before the pregnancy has reached a safe point for delivery. These tocolytic drugs work by relaxing the uterine muscle and stopping or slowing contractions. However, these medications are used cautiously and only when the benefits outweigh the risks, as stopping labor is not always advisable if there is significant bleeding.4

Throughout the pregnancy, women with placenta praevia undergo more frequent ultrasound examinations than those with normal pregnancies. These imaging tests allow doctors to monitor the position of the placenta, check whether it is moving away from the cervix as the uterus grows, and assess the baby's growth and well-being. An ultrasound uses sound waves to create pictures of the inside of the womb and is completely safe for both mother and baby.1

The ultimate treatment for placenta praevia is delivery of the baby, and in nearly all cases, this must be done through a cesarean section or C-section. This surgical procedure involves making an incision in the mother's abdomen and uterus to remove the baby. A C-section is necessary because allowing the cervix to dilate during labor would tear the placenta away from the uterine wall, causing catastrophic bleeding that could be fatal to both mother and child. Most planned C-sections for placenta praevia are scheduled around 36 to 37 weeks of pregnancy, once the baby's lungs are mature enough to function outside the womb.1

The duration of treatment extends throughout the remainder of the pregnancy once placenta praevia is diagnosed. Some women may spend weeks on bed rest, either at home or in the hospital, depending on their symptoms. The period after a C-section delivery also requires recovery time, typically 6 to 8 weeks before a woman can return to normal activities.4

Side Effects and Complications of Standard Treatment

The management strategies for placenta praevia, while necessary, can have side effects and complications. Extended bed rest, though protective, can lead to muscle weakness, blood clots in the legs, and emotional stress from isolation and inactivity. Women on prolonged bed rest may experience mood changes, anxiety, or depression as they cope with the restrictions on their activities and worry about their pregnancy.5

Corticosteroid injections, used to mature the baby's lungs, are generally safe but can occasionally cause temporary changes in the mother's blood sugar levels, particularly in women with diabetes. Some women experience insomnia or mood changes for a few days after receiving these injections.4

The C-section delivery itself carries surgical risks, including infection at the incision site, increased blood loss compared to vaginal delivery, and a longer recovery period. Women who have had a C-section are also at slightly higher risk for placenta praevia in future pregnancies, as uterine scarring can influence where the placenta attaches.1

One of the most serious complications associated with placenta praevia is postpartum hemorrhage, which is severe bleeding after delivery. This occurs because the lower part of the uterus, where the placenta was attached, does not contract as strongly as the upper part, making it harder to stop bleeding after the placenta is removed. In rare cases, the bleeding may be so severe that a hysterectomy—surgical removal of the uterus—becomes necessary to save the mother's life, resulting in permanent inability to have more children.6

Another complication that can occur with placenta praevia is placenta accreta spectrum, where the placenta grows too deeply into the uterine wall and cannot separate properly after delivery. This condition dramatically increases the risk of severe bleeding and often requires hysterectomy. Women with previous C-sections or uterine surgeries face higher risks of developing this complication when they also have placenta praevia.6

Emerging Research and Clinical Trial Investigations

While standard treatment for placenta praevia has remained largely unchanged for years—focusing on monitoring, activity restriction, and planned C-section delivery—researchers continue to explore ways to improve outcomes for mothers and babies affected by this condition. Currently, there are no specific medications or therapies being tested in clinical trials exclusively for placenta praevia, as the condition's management is primarily surgical and supportive rather than pharmaceutical.

However, research efforts are underway in related areas that may eventually benefit women with placenta praevia. Scientists are investigating better imaging techniques to predict which cases of early-diagnosed placenta praevia will resolve on their own and which will persist, requiring intervention. Advanced ultrasound methods and magnetic resonance imaging (MRI) techniques are being refined to provide more accurate assessment of placental position and attachment depth, which helps identify women at highest risk for complications like placenta accreta spectrum.6

Research is also focused on understanding the biological mechanisms that lead to abnormal placental implantation. Studies examining the role of uterine scarring, inflammation, and blood vessel development in the endometrium (the lining of the uterus) aim to uncover why some women develop placenta praevia. Understanding these underlying causes could eventually lead to preventive strategies or early interventions, though such treatments remain theoretical at this stage.6

Clinical trials in maternal-fetal medicine often include women with placenta praevia as part of broader studies on high-risk pregnancies. These studies may examine optimal timing for corticosteroid administration, compare different surgical techniques for C-section delivery in placenta praevia cases, or evaluate protocols for managing massive bleeding during delivery. Such research, typically conducted in Phase III trials comparing established approaches, helps refine best practices even when no new drugs are involved.6

Some research institutions in the United States and Europe are exploring whether certain blood markers or genetic factors can predict a woman's risk of developing placenta praevia or associated complications. These biomarker studies are in early phases, essentially Phase I and II research focused on identifying and validating predictive factors rather than testing treatments. If successful, such markers could allow for earlier identification of at-risk pregnancies and more proactive management.6

Most common treatment methods

• Activity modification and bed rest
  • Reducing physical activities and strenuous exercise to minimize risk of bleeding
  • Complete bed rest in hospital for women experiencing bleeding episodes
  • Avoiding sexual intercourse after 28 weeks of pregnancy
  • Avoiding insertion of anything into the vagina including tampons and douches
• Close monitoring and surveillance
  • Frequent ultrasound examinations to track placental position and baby's growth
  • Continuous fetal heart rate monitoring during hospitalization
  • Regular blood count checks to monitor for anemia from bleeding
  • Hospital admission for observation when bleeding occurs
• Medications to support pregnancy and prepare for early delivery
  • Corticosteroid injections to accelerate fetal lung development if early delivery is anticipated
  • Tocolytic drugs to prevent or slow premature labor contractions
  • Rhogam injections for women with Rh-negative blood type
  • Blood transfusions to replace blood lost during severe bleeding episodes
• Surgical delivery
  • Planned cesarean section delivery around 36 to 37 weeks of pregnancy
  • Emergency C-section if severe bleeding occurs before planned delivery date
  • Potential hysterectomy if bleeding cannot be controlled after delivery